<DOC>
	<DOCNO>NCT02660372</DOCNO>
	<brief_summary>The aim study show non-inferiority two brand simeticone adult patient suffer functional dyspepsia .</brief_summary>
	<brief_title>Efficacy Safety Two Simeticone Brands Adults With Functional Dyspepsia</brief_title>
	<detailed_description>This multi-center , randomize , observer-blind , parallel-group , 8-weeks , non-inferiority clinical trial compare efficacy safety two brand Simeticone symptomatic treatment functional dyspepsia adult .</detailed_description>
	<mesh_term>Dyspepsia</mesh_term>
	<mesh_term>Gastritis</mesh_term>
	<mesh_term>Simethicone</mesh_term>
	<criteria>1 . Subjects age 18 year older suspect diagnosis functional dyspepsia accord Rome III criterion ( see Appendix A ) e.g . subject suffer bothersome postprandial fullness early satiation epigastric pain epigastric burning AND evidence structural disease ( include upper GI endoscopy ) likely explain symptom . Criteria fulfil last 3 month . Symptom onset least 6 month prior diagnosis . 2 . Have Body Mass Index ( BMI ) 18.530 . 3 . Absence significant structural/organic abnormality abdominal ultrasound upper gastrointestinal endoscopy perform within last 3 month prior baseline exclude structural cause symptom . 4 . Negative Helicobacter Pylori urea breath test . 5 . Presence least three assess ten symptom judge least moderate severe intensity , assess withdrawal medication potentially affect gastrointestinal tract least 7 day washout period . 6 . Females childbearing potential must negative urine pregnancy test baseline visit . 7 . Male nonpregnant , nonlactating female agree contraceptive requirement ( include female partner 's use highly effective form birth control least 3 month study , study 3 month last dose study drug ) outline Section 10.7.4 . 8 . Able read understand local language ; 9 . Provide sign date informed consent form prior studyrelated procedure ; 10 . Willing able comply study procedure attend schedule visit duration study . 1 . Subjects meet diagnostic Rome III criterion Irritable Bowel Disease ( IBS ) ( see Appendix A ) . 2. ) severe gastroesophageal reflux symptom ( typical symptom heartburn , regurgitation , dysphagia , odynophagia , and/or sign reflux upper GI endoscopy ) Screening visit . b ) predominant gastroesophageal reflux symptom define Subject 's Symptom Severity Score 2 heartburn regurgitation Baseline visit 7days washout period ( see questionnaire Appendix B ) . 3 . Significant medical condition may interfere subject 's participation study , e.g . diabetes mellitus , thyroid dysfunction , renal insufficiency , congestive heart failure , electrolyte disturbance autoimmune disease require immunosuppressive treatment . 4 . Known hepatic , biliary pancreatic disease . 5 . Known lactose gluten intolerance celiac disease . 6 . Known HIV positive AIDS . 7 . Suspected alcohol substance abuse ( e.g. , amphetamine , benzodiazepine , cocaine , marijuana , opiates ) . 8 . Unwillingness inability withdraw abstain medication likely affect gastrointestinal function symptom 7days washout period throughout study period , include follow drug : gastrointestinal medication include antispasmodic , prokinetics , proton pump inhibitor , H2 blocker , antacid , alginate , bismuth preparation , sucralfate , misoprostol , charcoal , diosmectite , enzyme ( e.g . Kreon® , Mezim® ) . medication could interfere gastrointestinal function e.g . antibiotic ( except local application ) , theophylline , NSAIDs ( except lowdose aspirin prevention heart disease ) , opioid analgesic , codeine , ulcerogenic substance ( e.g . oral glucocorticoid ) , anxiolytic , neuroleptic , antidepressant , and/or others judgment investigator . 9 . Females pregnant breastfeeding . 10 . Males pregnant partner partner currently try become pregnant . 11 . Known sensitivity investigational product . 12 . Subjects previously screen ineligible randomized receive investigational product . 13 . Currently participate another clinical trial do past 30 day . 14 . Subjects related person involve directly indirectly conduct study ( i.e. , principal investigator , subinvestigators , study coordinator , site personnel , employee Johnson &amp; Johnson LLC McNeil AB subsidiary , contractor Johnson &amp; Johnson LLC McNeil AB , family ) . 15 . Other severe , acute chronic , medical psychiatric condition ( ) laboratory abnormality may increase risk associate study participation investigational product administration may interfere interpretation study result , judgment investigator , would make subject inappropriate entry study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>